Nasdaq
$6.87▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $446.7MShares out 65.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 2d agoPre-market26.10.22 21:506-KKey event#●●●#●●●
EUPRAXIA PHARMACEUTICALS INC.
Eupraxia Pharmaceuticals announced its participation in several upcoming global healthcare conferences and the hosting of a virtual Analyst Day between October and November 2026. Notably, the company will hold a dedicated presentation session on November 13, 2026, to discuss its EP-104GI candidate for eosinophilic esophagitis.…more
$6.87+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Regular26.10.15 23:136-KKey event
EUPRAXIA PHARMACEUTICALS INC.
Eupraxia Pharmaceuticals has reached its target enrollment of 120 patients for the Phase 2b clinical trial of EP-104GI for the treatment of eosinophilic esophagitis. No treatment-related serious adverse events have been reported to date, and the company expects to report interim analysis results in December 2026.…more
$6.87+0.00%vs prev closeView filingShare - 10.9Pre-market26.10.09 21:276-KKey event
EUPRAXIA PHARMACEUTICALS INC.
Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis have been accepted for presentation at the ACG and UEG medical conferences. The data demonstrates sustained improvements in dysphagia and histopathological features over 52 weeks, with interim results from the Phase 2b portion expected in December 2026.…more
$6.87+0.00%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:30#●●●#●●●
Eupraxia Pharmaceuticals to Participate in Conferences and Host Virtual Analyst Day…more
Eupraxia Pharmaceuticals announced its participation in several upcoming investor conferences and a virtual Analyst Day. These events are standard corporate IR activities and do not provide immediate material impact on the company's valuation.…more
$6.87+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15Pre-market26.10.15 21:00
●●●●●●●● ●●●●● ●●●●●●
Eupraxia Pharmaceuticals has reached its target enrollment for the Phase 2b clinical trial of its eosinophilic esophagitis treatment, EP-104GI. While the company expects to report interim data in December, the progress remains at a clinical development stage with neutral impact on stock sentiment.…more
$6.87+0.00%vs prev close - 10.9Pre-market26.10.09 21:00
●●●●●●●● ●●●●● ●●●●●●
Eupraxia Pharmaceuticals will present clinical data from its Phase 1b/2 trial of EP-104GI for eosinophilic esophagitis at upcoming gastroenterology conferences. This presentation serves as an academic update and does not constitute a material financial or regulatory milestone.…more
$6.87+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report